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Although certain microbial lipids are toxins, the structural features important for cytotoxicity
remain unknown. Increased functional understanding is essential for developing therapeutics
against toxic microbial lipids. Group B Streptococci (GBS) are bacteria associated with pre-
term births, stillbirths, and severe infections in neonates and adults. GBS produce a pig-
mented, cytotoxic lipid, known as granadaene. Despite its importance to all manifestations of
GBS disease, studies towards understanding granadaene’s toxic activity are hindered by its
instability and insolubility in purified form. Here, we report the synthesis and screening of
lipid derivatives inspired by granadaene, which reveal features central to toxin function,
namely the polyene chain length. Furthermore, we show that vaccination with a non-toxic
synthetic analog confers the production of antibodies that inhibit granadaene-mediated
hemolysis ex vivo and diminish GBS infection in vivo. This work provides unique structural
and functional insight into granadaene and a strategy to mitigate GBS infection, which will be
relevant to other toxic lipids encoded by human pathogens.
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M icrobial lipids with hemolytic or cytotoxic activity havebeen reported from several human bacterial pathogens,including mycolactone fromMycobacterium ulcerans1,2,
rhamnolipids from Pseudomonas aeruginosa3,4, commendamide
from Bacteroides spp.5, and the pigmented ornithine rhamno-
polyene (granadaene) from Group B Streptococcus (GBS)6,7.
However, structure–activity studies demonstrating the features
important for cytotoxicity are lacking, hindering the development
of therapies or vaccines targeting these compounds. GBS is a β-
hemolytic Gram-positive bacterium frequently associated with
preterm birth and severe neonatal infections8–10. Although clin-
ical trials involving maternal vaccination of a trivalent capsular
polysaccharide-based CRM197 conjugate were shown to provide
serotype-specific antibody11 and a six-valent vaccine is being
explored12, no Food and Drug Administration-approved vaccine
exists to date for GBS prevention. In recent years, the incidence of
invasive GBS disease, including bloodstream, skin, soft tissue, and
joint infections, has increased in non-pregnant adults, particularly
among the elderly and persons with comorbidities13–15. These
trends, along with concerns regarding the emergence of
antibiotic-resistant GBS strains, have increased the urgency for
novel preventive and curative treatments16,17.
Granadaene produced by GBS confers pigmentation18 and
hemolytic activity6,7 and is a major contributor to all manifes-
tations of GBS disease, making it an attractive therapeutic target.
Hemolytic and hyper-hemolytic GBS strains have been isolated
from patients with GBS infections, including women in preterm
labor and adults with invasive infections6,19–22. Furthermore,
non-hemolytic GBS strains are typically virulence-attenuated, and
hyper-hemolytic GBS strains exhibit increased virulence in var-
ious models of infection, including sepsis, meningitis, and pre-
term birth6,20,23–25. In addition, we showed that purified
granadaene isolated from GBS is hemolytic and cytotoxic to
innate immune cells, including mast cells, macrophages, and
neutrophils6,7,24,26. Despite these advances, the structural features
responsible for hemolysis and cytotoxicity are unknown.
A major barrier for elucidating the functions of GBS ornithine
rhamnopolyene is its limited solubility and instability in its
purified form, which is typical for compounds containing long
polyene chains27. Here, we use chemical synthesis to overcome
these challenges associated with studying polyenic compounds.
Through the synthesis of lipid derivatives featuring key structural
components of granadaene, we demonstrate how the polyene
chain length and polar head groups influence hemolytic activity.
Further, we identify a non-toxic analog, which, unlike grana-
daene, is tolerated by cells of the adaptive immune system and
diminished GBS infection when incorporated into a vaccine
formulation. Together, these data advance our chemical, mole-
cular, and biological understanding of a key GBS virulence factor
whose mechanism has eluded us thus far. Moreover, our findings
provide proof-of-concept for a promising therapeutic strategy to
mitigate the effects of this lipid toxin during infection.
Results
Polyene chain length is critical for hemolysis. To understand
components necessary for granadaene-mediated hemolysis and
cytolysis, we identified target compounds for synthesis that
contained chemical features analogous to those in granadaene
(Fig. 1a) and were sufficiently soluble and stable in vitro. We
focused on three relevant moieties: the polyene chain, the term-
inal amino acid, and the rhamnose. The chemical structure of
each target compound that was synthesized is listed in Table 1.
The synthetic compounds were designed to contain a varying
number of alkenes, ranging from one to nine, denoted in the
compound names by “P” and then the number of alkenes in the
polyene chain (e.g., P9). The rhamnose group found in grana-
daene (Fig. 1a) was replaced with hydrophobic tert-butyldi-
methylsilyl (TBS)-protecting group (denoted by “p”) in some
target compounds, namely pP7X, pP7, pP9, and pP1, to ensure
reasonable solubility of these derivatives during the synthetic
sequence and subsequent biological tests. One compound, R-P4,
was sufficiently stable, which enabled us to include a terminal
rhamnose moiety without compromising solubility. In other
compounds, such as P7 and P9, a hydroxyl group was included to
test the effect of a hydrophilic head group. Because the L-orni-
thine residue at the terminus of granadaene was previously
observed to lactamize in several synthetic reaction conditions28,
which could confound interpretation of the biological assays, it
was replaced with a simpler L-alanine residue in all synthetic
compounds except pP7X, which contained a carboxyl group
instead; this compound was synthesized to test the effect of the
terminal amino acid on hemolytic activity. Each of the target
compounds was fully characterized (see Methods and Supple-
mentary Materials) and analyzed by mass spectrometry and
proton nuclear magnetic resonance (1H NMR) and carbon-13
NMR (13C NMR) (see Supplementary Materials).
To examine if analogs had hemolytic activity, we first examined
their ability to lyse red blood cells (RBCs) on red blood agar plates
and then quantitatively examined them for lysis of RBCs using
methods described6. While pP1, R-P4, and P7 showed no
hemolytic activity (Supplementary Fig. 1), hemolysis was
observed in pP7X, pP7, pP9, and P9 (Fig. 1b–e), which indicates
that the length of the polyene chain facilitates hemolysis. In
addition, these results suggest that the protecting group is
important for the activity of compounds with shorter polyene
chains. The proposed role of the polyene chain length and head
groups in granadaene-mediated hemolysis is illustrated in Fig. 2.
Except for P9, no statistically significant difference in hemolysis
was observed between compounds resuspended in DTS (DMSO
(dimethyl sulfoxide) + 0.1% TFA (trifluoroacetic acid)+ 20%
starch) versus DMSO, indicating that starch, which is used to
stabilize purified granadaene solutions6, may be important to
stabilize longer polyene chains that are unprotected. Of note,
no hemolysis was observed in RBCs treated with DTS or DMSO
alone (Supplementary Fig. 1). Collectively, these findings empha-
size the importance of the length of the polyene chain to GBS
hemolysis, thus providing insight into the chemical features key to
granadaene activity.
Granadaene is cytotoxic to CD4+ T and B cells. In addition to
lysis of RBCs, we have described the cytotoxic activity of grana-
daene to various innate immune cells, including mast cells,
neutrophils, and macrophages6,7,24,26. To date, the effect of
granadaene on adaptive immune cells has not been described, but
is critical to determine for vaccine strategies. Furthermore, anti-
bodies specific to this toxin have not been identified. As a few
studies have reported that GBS can activate CD4+ T cells29,30, we
explored the effect of granadaene on adaptive immune cells.
First, primary CD4+ T or B cells isolated from the blood of
healthy adult humans were incubated with GBS that were either
hyper-hemolytic (NCTC10/84, serotype V) or non-hemolytic
(NCTC10/84ΔcylE; the non-hemolytic strain lacks the cylE gene,
which is necessary for granadaene production31) at a multiplicity
of infection (MOI) of 10 for 1 h. We noted that the hyper-
hemolytic strains induced cell death, which was significantly
greater compared to cells treated with non-hemolytic GBS
(Fig. 3a). These findings indicate that adaptive immune cells are
susceptible to death by hyper-hemolytic GBS strains. Of note,
only minimal cytotoxicity (<10%) was observed with modestly
hemolytic GBS strains (A909, serotype Ia; and COH1, serotype III),
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similar to our previous observations with innate immune
cells7,24,26. Next, to explore the mechanism and kinetics of cell
death, we measured propidium iodide (PI) uptake and Annexin V
(AV) staining in both cell types at 0, 15, and 30min following
incubation with hyper-hemolytic GBS at an MOI of 10. We found
that at 0 min, most cells were negative for both PI and AV, but
after just 15min of incubation, a proportion of each cell type were
positive for PI and AV, and by 30min, more cells became positive
for both PI and AV (Fig. 3b). The rapid phenotypic shift of PI
positive/AV negative (PI−/AV−) to PI positive/AV positive
(PI+/AV+) suggests that CD4+ T and B cells underwent a lytic
























































































































Fig. 1 The polyene chain length is important for hemolytic activity. a Granadaene contains a terminal rhamnose, a polyene chain consisting of 12 double
bonds, and a terminal ornithine. b–e Synthetic analogs of granadaene (structures shown) were resuspended in DTS (DMSO+ trifluoroacetic acid (TFA,
0.1%)+ starch (20%)) or DMSO. The analogs were co-incubated with human red blood cells at 250, 125, and 62.5 µM for 1 h at 37 °C, and hemoglobin
release in cell supernatants was quantified to determine percent hemolysis relative to Triton X-100 (0.1%)-treated positive controls and PBS-treated
negative controls. Mean and standard error from three independent experiments are shown. Differences in hemolysis between DTS resuspension and
DMSO resuspension for a given concentration of each compound were analyzed using a two-way ANOVA with Tukey’s post test. pP7X: 250 μM, p=
0.9959, 125 μM, p= 0.2079, 62.5 μM, p= 0.9007; pP7: 250 μM, p= 0.9524, 125 μM, p= 0.8823, 62.5 μM, p= 0.8375; pP9: 250 μM, p= 0.9999,
125 μM, p= 0.5592, 62.5 μM, p > 0.9999; P9: 250 μM, p < 0.0001, 125 μM, p= 0.6957, 62.5 μM, p > 0.9999. Additionally, 5 µL of each synthetic analog at
0.02M concentration was spotted onto red blood agar plates and allowed to incubate at 37 °C overnight. The hemolytic effect of each compound on red
blood agar is shown. ****, p < 0.0001. n.s., Not significant.
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30min of treatment with non-hemolytic GBS (Supplementary
Fig. 2). When CD4+ T cells were imaged using scanning electron
microscopy (SEM) after exposure to hyper-hemolytic GBS, non-
hemolytic GBS, or phosphate-buffered saline (PBS), striking
changes in cell surface morphology were observed in cells treated
with hyper-hemolytic GBS, but not with cells exposed to non-
hemolytic GBS or saline controls (PBS) (Fig. 3c).
To determine if granadaene alone was sufficient for induction of
these cytolytic effects, the above assays were performed with purified
granadaene (0.5 µM), equivalent amount of extract from non-
hemolytic GBS (GBSΔcylE extract), or solvent (DTS) alone. Similar
to our observations with live bacteria, significantly greater cell death
was observed when CD4+ T and B cells were exposed to granadaene
compared to the controls (GBSΔcylE extract or DTS) (Fig. 3d), and
these cells also rapidly switched to PI+/AV+ (Fig. 3e), while the vast
majority of controls remained PI−/AV− (Supplementary Fig. 2).
Further, SEM revealed that CD4+ T cells treated with granadaene
exhibited morphological changes on the cell surface, unlike cells
treated with GBSΔcylE extract or DTS (Fig. 3f). Together, these
findings demonstrate that granadaene and hyper-hemolytic GBS
strains are cytotoxic to cells of the adaptive immune system.
Synthetic analog R-P4 is not toxic to T and B cells. Our results
above indicate that granadaene is likely to be a poor candidate for
incorporation into a vaccine for prevention of GBS infection. We
reasoned that a non-toxic synthetic analog of the GBS ornithine
rhamnopolyene may be better suited in a vaccine formulation.
Because R-P4 was non-hemolytic and contains structural com-
ponents similar to granadaene of all the synthesized analogs (i.e.
terminal rhamnose, polyene chain, and terminal amino acid), we
tested its cytotoxicity to CD4+ T and B cells. We found that
primary human CD4+ T or B cells exposed to R-P4 (20 μM) for
1 h showed minimal cell death (Fig. 4a). Next, we determined
whether CD4+ T and B cells could respond to activation stimuli
in the presence of R-P4. To this end, primary human CD4+
T cells were stimulated with PMA (phorbol 12-myristate 13-
acetate) and αCD3ε, and primary human B cells were stimulated
with αCD40 and interleukin-4 (IL-4). Cells were then treated with
PBS, R-P4 (20 μM), or purified granadaene (5 μM). After 48 h,
cells were stained for the canonical activation marker CD6933,
resuspended in DAPI (2-[4-(aminoiminomethyl)phenyl]-1H-
indole-6-carboximidamide hydrochloride) as a viability stain, and
analyzed by flow cytometry (see gating strategy in Supplementary
Fig. 3). Compared to unstimulated controls treated with PBS,
stimulated CD4+ T and B cells exposed to R-P4 up-regulated
CD69 (Fig. 4b, c). Furthermore, CD69 expression in stimulated
cells exposed to R-P4 was no different than stimulated cells
exposed to PBS (Fig. 4b, c). Of note, <10% of cells treated with
Table 1 The chemical structures and estimated polyene chain lengths and calculated logarithm of its partition coefficient
between n-octanol and water (cLogP) of synthetic analogs and granadaene.
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granadaene were viable (DAPI−) (Supplementary Fig. 3), so this
group was excluded from the CD69 analysis in both cell types.
However, the proportion of DAPI− cells was no different among
other treatment groups in either cell type (Supplementary Fig. 3).
Collectively, these results indicate that CD4+ T and B cells sur-
vive and respond to activating stimuli when exposed to R-P4.
Vaccination with R-P4 analog diminished GBS infection. Next,
we hypothesized that vaccination with R-P4 may generate an
immune response that antagonizes the effects of granadaene
during systemic GBS infection. Given that hyper-hemolytic GBS
cause lethal infection in adult mice34, we used the adult systemic
model of GBS infection to test if R-P4 could diminish infection
with a hyper-hemolytic strain. To this end, mice were immunized
(intraperitoneally (IP)) with an emulsion of R-P4 (10 μM in PBS)
in complete Freund’s adjuvant and boosted 14 days later with the
same dose of R-P4 in incomplete Freund’s adjuvant (see Meth-
ods). On day 21 after initial vaccination, mice were euthanized for
plasma collection or were challenged (IP) with the hyper-
hemolytic GBS strain NCTC10/84 (Fig. 5a). As controls, mice
were injected with adjuvant alone on the same vaccination
schedule.
Immunoblots revealed that plasma from mice vaccinated with
R-P4 contained more immunoglobulin G (IgG) bound to purified
granadaene compared to adjuvant-only controls (Fig. 5b).
Furthermore, plasma from analog-vaccinated mice inhibited
granadaene-mediated hemolysis in contrast to plasma from
adjuvant-only controls (Fig. 5c, n= 10/group). The amount of
granadaene-bound IgG detected in plasma significantly correlated
with inhibition of granadaene hemolysis (Supplementary Fig. 4),
suggesting that granadaene-reactive IgG partially neutralizes
toxin function. At 24 h post-bacterial challenge, mice were
euthanized and GBS colony-forming units (CFU) were enumer-
ated in the spleen, lung, brain, and blood. Significantly fewer
CFUs were recovered from the tissues and blood of analog-
vaccinated mice compared to adjuvant-only control mice (n=
24/group) (Fig. 5d), indicating that immunization with R-P4
limited bacterial dissemination. Together, these data demonstrate
that vaccination with a non-toxic granadaene analog generates
granadaene-specific antibodies with neutralizing properties and
protects against infection with hyper-hemolytic GBS.
Discussion
Microbial lipids produced by several human pathogens, including
mycolactone from Mycobacterium ulcerans1,2, rhamnolipids from
Pseudomonas aeruginosa3,4, commendamide from Bacteroides
spp.5, and granadaene from GBS6,7, contribute to pathogenesis by
killing host cells. Yet, structure–function studies demonstrating
the underpinnings of cytotoxicity in such compounds are lacking,
and no strategies exist to attenuate toxin activity during infection.
Here, we use chemical synthesis to understand the characteristics
important for hemolytic activity in the ornithine rhamnopolyene
produced by GBS. Furthermore, we provide proof of concept for a
vaccine that mitigates the effect of this lipid toxin during
infection.
Our studies indicate that the polyene chain length is a key
factor in the ability of granadaene to lyse RBCs. We show that
lipids with one or four alkenes (pP1 and R-P4) are not hemolytic
despite having a terminal amino acid and protecting group
(Supplementary Fig. 1). Similarly, polyenes containing seven
double bonds were non-hemolytic (P7) unless the terminal polar
group was replaced with a hydrophobic group such as TBS

































































Fig. 2 Proposed role of polyenes and polar head groups for granadaene-mediated hemolysis and cytolysis. The polyene chain of granadaene spans the
length of the target cell’s lipid bilayer and the two polar head groups, rhamnose and ornithine, allow for stable insertion of the GBS ornithine
rhamnopolyene into the cell membrane, leading to membrane disruption and hemolysis or cytolysis. Shorter polyenes such as those containing seven
double bonds are hemolytic only when one polar end is replaced with a hydrophobic group (e.g., TBS), as in pP7, in which the molecule stably inserts in the
membrane due to the compatibility between the hydrophobic lipid bilayer and the TBS group. However, if both polar ends are maintained in compounds
with shorter polyenes, as in P7 or R-P4, no hemolytic activity is observed because stable insertion into the cell membrane is not favored. Once the polyene
chain reaches a sufficient length, as in P9, some hemolytic activity is observed even when both polar head groups are maintained. Together, this suggests
that the length of the polyene chain and polar head groups found in granadaene are key to stable membrane disruption of host cells.
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(pP7X, pP7). In contrast, lipids with nine alkenes (P9, pP9) were
hemolytic, with or without the TBS-protecting group (Fig. 1).
Interestingly, a much greater concentration of each hemolytic
analog was required for activity (62.5–250 μM, Fig. 1) compared
to that previously observed for granadaene (0.1–1 μM)6. We
predict that this may be due to the length of the polyene
chains; the predicted length of granadaene (>32 Å) is longer
when compared to the length of each analog (<24 Å, Table 1).
Our data suggest that granadaene’s hydrophobic polyene moiety
can span the thickness of the target cell’s plasma membrane
(30–40 Å)7,35–37, with the terminal ornithine and rhamnose ser-
ving as hydrophilic polar head groups that allow for stable
insertion. The ability of the polyene moiety of pP7X, pP7, P9,
and pP9 to span the plasma membrane partially, but not entirely,
could explain the observed attenuated hemolytic activity relative
to granadaene. Additionally, calculated partition coefficients for
more active lipids are in agreement with a dynamic and favorable
lipophilic interaction with lipidic cellular domains38.
The observation that P7, which is similar in length to pP7, is
non-hemolytic (Supplementary Fig. 1) suggests an additional role
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Fig. 4 R-P4 is non-toxic to T and B cells. a Primary human CD4+ T cells (left) and B cells (right) were incubated with R-P4 (20 μM) or granadaene
(0.5 μM) for 1 h at 37 °C, and cytotoxicity was measured by LDH release into cell supernatant relative to 100% lysis (Triton X-100 (0.1%)) and 0% lysis
(PBS) controls. Mean and standard error from three independent experiments are shown. Groups were compared with a two-tailed unpaired t test. CD4+
T cells: p= 0.0024, B cells: p= 0.0084. b Primary human CD4+ T cells were treated with PMA (10 ng/mL) and anti-CD3ε (100 μg/mL) (stimulated) or
media alone (unstimulated). Then, cells were treated with either PBS or R-P4 (20 μM) and incubated at 37 °C for 48 h. Cells were stained for CD69,
resuspended in DAPI (0.5 μM), and analyzed by flow cytometry. Percent CD69+ of DAPI− cells from three independent experiments are represented
with mean and standard error. Treatment groups were compared using one-way ANOVA with Tukey’s post test. PBS (unstimulated) vs. PBS (stimulated):
p < 0.0001, PBS (unstimulated) vs. R-P4 (stimulated): p < 0.0001, PBS (stimulated) vs. R-P4 (stimulated): p= 0.8151. c Primary human B cells were
treated with IL-4 (20 ng/mL) and anti-CD40 (5 μg/mL) (stimulated) or media alone (unstimulated). Then, cells were treated with either PBS or R-P4
(20 μM) and incubated at 37 °C for 48 h. Cells were stained for CD69, resuspended in DAPI (0.5 μM), and analyzed by flow cytometry. Percent CD69+ of
DAPI− cells from three independent experiments are represented with mean and standard error. Treatment groups were compared using one-way
ANOVA with Tukey’s post test. PBS (unstimulated) vs. PBS (stimulated): p= 0.0091, PBS (unstimulated) vs. R-P4 (stimulated): p= 0.0453, PBS
(stimulated) vs. R-P4 (stimulated): p= 0.3893. *, p < 0.05. **, p < 0.01. ****, p < 0.0001. n.s., Not significant.
Fig. 3 Granadaene is cytolytic to T and B cells. a Primary human CD4+ T and B cells were incubated with either hyper-hemolytic GBS (HH GBS) or non-
hemolytic GBS (NH GBS) at an MOI of 10 for 1 h at 37 °C, and cytotoxicity was measured by the release of lactate dehydrogenase (LDH) into the cell
supernatant relative to 100% lysis (Triton X-100 (0.1%)) and 0% lysis (PBS) controls. Mean and standard error from three independent experiments are
shown. A two-tailed unpaired t test was used to compare groups. CD4+ T cells: p= 0.0075, B cells: p= 0.0005. b PI uptake and Annexin V staining were
measured using flow cytometry following incubation with HH GBS at an MOI of 10 at the indicated time points. c CD4+ T cells were imaged using scanning
electron microscopy (SEM) following incubation with PBS, NH GBS, or HH GBS (MOI= 10) for 1 h. Images are representative of three experiments. Scale
bars are 1 μm. d Primary human CD4+ T and B cells were incubated with purified granadaene (0.5 µM), equivalent amount of extract from NH GBS
(GBSΔcylE), or solvent (DTS), and cell death was measured by LDH release in supernatants, as above. Mean and standard error from three independent
experiments are shown. Groups were compared with one-way ANOVA with Tukey’s post test. CD4+ T cells: granadaene vs. ΔcylE extract: p= 0.0002,
granadaene vs. DTS: 0.0002, ΔcylE extract vs. DTS: p= 0.9928. B cells: granadaene vs. ΔcylE extract: p= 0.0020, granadaene vs. DTS: 0.0032, ΔcylE
extract vs. DTS: p= 0.8513. e PI uptake and Annexin V staining were measured using flow cytometry in each cell type following incubation with purified
granadaene (0.5 µM) at the indicated time points. f CD4+ T cells were imaged using SEM following incubation with DTS, GBSΔcylE extract, or granadaene
(0.5 µM) for 1 h. Images are representative of three experiments. Scale bars are 1 μm. **, p < 0.01. ***, p < 0.001. ****, p < 0.0001. n.s., Not significant.
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for the terminal head groups in hemolytic activity. It is plausible
that the terminal, hydrophilic hydroxyl group in P7 being
imbedded within the highly hydrophobic lipid bilayer destabilizes
the seven-alkene analog, whereas the hydrophobic TBS-protecting
group in pP7 allows for stable insertion into the cell’s lipid bilayer.
Our finding that P9, which does not have a TBS group but a
terminal hydroxyl group, is hemolytic (Fig. 1e) suggests that a
longer polyene chain (i.e., nine alkenes versus seven alkenes)
stabilizes insertion of the polyene into the cell membrane. A
limitation of our work is the present inability to synthesize com-
pounds with polyene chains containing more than nine alkenes
due to rapid denaturation during synthesis. Synthesis of analogs
with longer polyenes, such as those with 12 double bonds like
granadaene, will be essential in confirming the model we propose.
Recently, microbial lipids have gained appreciation for their
importance as antigens in the host response against bacterial
infections39. Here, we show that granadaene kills cells of the
adaptive immune system, including CD4+ T and B cells (Fig. 3).
Death in these cells was marked by cell membrane permeability
and damage, as indicated by rapid PI/AV positivity and SEM
imaging. Our findings with adaptive immune cells could at least
partially explain why antibodies specific to granadaene have never
been isolated from infected patients or produced in the labora-
tory; the cytotoxic effect of the GBS ornithine rhamnopolyene to
the very cells involved in antibody production inhibit their
function. As such, granadaene is likely a poor candidate to serve
as an antigen in a GBS vaccine formulation.
We hypothesized that a non-toxic analog with structural
similarities to granadaene, namely the rhamnose, polyene chain,
and amino acid, may serve as an antigen that would prompt an
immune response with cross-reactivity to granadaene during GBS
infection. We show that compound R-P4 is non-toxic to CD4+ T
and B cells and that these cells can respond to activating stimuli
when exposed to R-P4 (Fig. 4). Thus, we selected R-P4 as the
immunizing agent for our vaccination studies. We found that
plasma from mice vaccinated and boosted with R-P4 contained
class-switched antibodies that bound specifically to granadaene
(Fig. 5b). In addition, plasma from R-P4-vaccinated mice
inhibited hemolytic activity of granadaene ex vivo more than
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Fig. 5 Vaccination with a non-toxic synthetic analog diminished GBS infection. a Mice were vaccinated with an emulsion of R-P4 (10 μM in PBS) in
complete Freund’s Adjuvant and boosted 14 days after initial vaccination using R-P4 in incomplete Freund’s Adjuvant. At 21 days, vaccinated mice were
euthanized for blood/plasma collection or were challenged (IP) with ∼1 × 108 CFU of hyper-hemolytic GBS strain NCTC10/84. As controls, mice receiving
adjuvant only were tested in parallel with the same schedule. b Approximately 4 μL solvent or purified granadaene (25 μM) was spotted on PVDF
membranes, which were then blocked and probed with plasma from analog-vaccinated or adjuvant-only mice (n= 10/group). Subsequently, the
membranes were probed with secondary goat anti-mouse IgG (Alexa Fluor 680) and analyzed on the Odyssey LI-COR Imaging System. Four
representative spots from each group are shown. Signal intensity of each spot was determined using the Image J software, and a two-tailed unpaired t test
was used to compare signal intensity between groups (p= 0.0020). Mean and standard error are shown. c Plasma (diluted 1:1000) from analog-
vaccinated mice or adjuvant-only only mice (n= 10/group) was pre-incubated with purified granadaene (0.3 μM) for 1 h and then incubated with human
red blood cells for 1 h. Percent inhibition of granadaene hemolysis was calculated (see Methods), and a two-tailed unpaired t test was used to compare
hemolysis inhibition by R-P4 plasma vs. control plasma (p= 0.0004). Mean and standard error are shown. d GBS CFU recovered from the blood, spleen,
lung, and brain of mice (n= 24) at 24 h post infection were compared using a two-tailed Mann–Whitney test. Blood: p= 0.0025, spleen: p= 0.0001, lung:
p= 0.0010, brain: p= 0.0002. *, p < 0.05. **, p < 0.01. ***, p < 0.001.
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granadaene-bound IgG in plasma significantly correlated with
granadaene inhibition (Supplementary Fig. 4). These findings
suggest that vaccination with R-P4 generated granadaene-specific
antibodies, which had toxin-neutralizing properties. The anti-
virulence factor effect of R-P4 vaccination was further supported
by results from infected mice; analog-vaccinated mice infected
with hyper-hemolytic GBS experienced less bacteremia and bac-
terial dissemination to peripheral organs, including the spleen,
lungs, and brain compared to adjuvant-only control mice
(Fig. 5c). Because granadaene has been shown to promote GBS
transmigration of the lung and blood brain barriers25,40, our
results suggest that vaccination with R-P4 limited GBS virulence
by counteracting the pathogenic effects of this toxin. We hypo-
thesize that the high degree of structural similarity between R-P4
and granadaene allowed for the production of antibodies with
affinity for granadaene that dampened the activity of this toxin
during GBS infection. Additional data on the dynamics of the
humoral and cell-mediated response during immunization and
the course of infection will lend greater insight into the
mechanisms of protection conferred by this vaccine formulation
and will inform the design of other vaccines that incorporate lipid
antigens.
In conclusion, our findings with synthetic analogs reveal the
structural components of granadaene that are important for host
cell lysis. Additionally, we overcome granadaene-mediated cyto-
toxicity of T and B cells by creating a vaccine using a non-toxic
granadaene analog, which prompted the generation of
granadaene-binding antibodies and reduced the harmful effects of
this toxin during GBS infection. Collectively, these studies pro-
vide proof of concept for a strategy to counteract a cytotoxic
microbial polyene that is critical to pathogenesis. These findings
have broad application to understanding the biological activity of
similar microbial lipid toxins and the development of targeted
therapeutics against them.
Methods
Ethics statement. Written informed patient consent for donation of human blood
was obtained with approval from the Seattle Children’s Research Institute Insti-
tutional Review Board (protocol #11117) per the Principles in the WMA
Declaration of Helsinki and Department of Health and Human Services Belmont
Report. Children under the age of 18 years were not recruited for donation of
human blood.
All animal experiments were approved by the Seattle Children’s Research
Institutional Animal Care and Use Committee (protocol ID IACUC00036) and
performed in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health (8th
Edition).
Chemicals. DMSO (Fisher Scientific), TFA (Thermo Fisher Scientific), and Difco
soluble starch (BD) were used to make DTS. All reagents used in the synthesis of
granadaene-inspired lipids were purchased from standard chemical suppliers and
used without further purification.
Bacterial strains. The wild-type (WT) GBS strains used in this study are A909
(serotype Ia) and NCTC10/84 (serotype V); these strains are clinical isolates
obtained from infected newborns41. Isogenic non-hemolytic ΔcylE mutants derived
from A909 and NCTC10/8431 were used as non-hemolytic controls.
Cultures of GBS were grown in tryptic soy broth (Difco Laboratories) at 37 °C
in 5% CO2. Culture growth for all bacterial strains was measured at 600 nm, and
bacterial strains were washed twice in PBS before being used in experiments.
Photographs of bacterial strains on blood agar (Remel) or Granada medium
(Hardy Diagnostics) were captured with an SLR camera (EOS Rebel XSi 12.2MP;
Cannon) with an 18–55 mm zoom lens and processed using Photoshop CC
(Adobe).
Isolation and purification of granadaene from GBS. Granadaene was isolated
from WT GBS A909 as described6,18,42. Approximately 500 mL cultures of WT
GBS A909 cultures were grown in Granada medium at 37 °C, in 5% CO2. Bacterial
cells were pelleted, washed three times with distilled water, and twice with DMSO.
The cell pellet was then resuspended in DMSO:0.1% TFA (Sigma-Aldrich) over-
night to extract granadaene, cell debris was pelleted, and the supernatant
containing grandaene was saved. The above process was repeated until the
supernatant obtained from GBS cells was clear. Granadaene was then precipitated
by the addition of 25% NH4OH (Scientific Products) to a final concentration of
0.25%. Precipitated granadaene was washed three times with high pressure liquid
chromatography (HPLC) grade water and twice in DMSO before redissolved in
DMSO:0.1%TFA. Granadaene was then column purified using HPLC with a Vydac
214TP C4 column. Purified fractions were pooled, precipitated with NH4OH,
washed twice with HPLC grade water, and then twice with DMSO, and lyophilized
to dryness. Lyophilized granadaene was stored at −80 °C, and working granadaene
solutions were dissolved in DMSO+ 0.1% TFA+ 20% starch (DTS) as needed.
The purification and isolation procedure were also performed on GBS A909ΔcylE
(non-pigmented/non-hemolytic isogenic mutant of WT A909). Extract from
A909ΔcylE was used as a control for granadaene in all experiments, along with the
DTS solvent. 1H NMR spectrum of purified samples was used as a criteria of purity
and identity.
Synthesis of GBS granadaene-inspired lipids. The entire procedure for the
synthesis of granadaene-inspired lipids is provided in Supplementary Materials.
General information: The synthetic approach was based on an iterative
sequence of Horner–Wadsworth–Emmons olefination reactions. Although many
other olefination reactions are known, this sequence was chosen for its preference
toward E stereoisomers, which is desirable for synthesis of the target compounds.
The complexity of the analysis of naturally occurring granadaene precluded an
exact analysis of the stereochemistry of the polyene chain, which was postulated to
be E. The stereochemical purity in such a long polyene is compromised and
therefore many diastereoisomers could contribute to the hemolytic activity. Given
this, we produced a mixture of diastereoisomers composed by the all E-
diastereoisomer and minor amounts of other Z-containing diastereoisomers, thus
more precisely mimicking natural granadaene.
Tetrahydrofuran (THF) was freshly distilled from Na. CH2Cl2 was freshly
distilled from P2O5. Thin layer chromatography was performed on aluminum-
backed plates coated with silica gel 60 (230–240 mesh) with F254 indicator.
The spots were visualized with ultraviolet light (254 nm). All chromatography
purifications were performed with silica gel 60 (40–60 μm). NMR spectra were
measured at room temperature. 1H NMR spectra were recorded at 400, 500,
and 600MHz. Chemical shifts are reported in p.p.m. using residual solvent
peak as reference (CHCl3: δ= 7.26 p.p.m., CH3OH: δ= 3.31 p.p.m., DMSO:
δ= 2.50 p.p.m.). 13C NMR spectra were recorded at 100, 125, and 150MHz
using broadband proton decoupling, and chemical shifts are reported in p.p.m.
using residual solvent peaks as reference (CHCl3: δ= 77.16 p.p.m., CH3OH:
δ= 49.0 p.p.m., DMSO: δ= 39.51 p.p.m.). Carbon multiplicities were assigned by
DEPT (distortionless enhancement of polarisation transfer) techniques. High-
resolution mass spectra were recorded on a mass spectrometer using electron
ionization at 70 eV. Racemic ethyl 3-hydroxybutanoate was used in the synthesis
of all granadaene derivatives, except for R-P4 owing to the presence of the
D-rhamnose subunit, which can generate different diastereosiomers. In this case,
(3R)-ethyl 3-hydroxybutanoate was used as the starting material. The known
compound ethyl 3-((tert-butyldimethylsilyl)oxy)butanoate was isolated as pure
sample and showed NMR spectra matching those of previously reported43–45.
General procedure for Horner–Wadsworth–Emmonds reaction (GP-1): A
mixture of the corresponding phosphonate (2.5 mmol), and NaH (2.5 mmol, 60%
purity) in THF (15 mL) was stirred at 0 °C for 10 min Then, the corresponding
aldehyde (1 mmol) was added dropwise for 10 min, and the mixture was stirred at
room temperature for 0.5–1.5 h. Then, saturated aqueous NH4Cl was added, and
THF was removed under reduced pressure. The residue was solved in EtOAc, and
the mixture was washed with saturated aqueous NH4Cl and brine, dried over
anhydrous Na2SO4, and the solvent was removed. Products were purified by flash
chromatography on silica gel (EtOAc/Hexane mixtures) and characterized by
spectroscopic techniques.
General procedure for DIBAL-H reduction of esters to alcohols (GP-2): To a
solution of the corresponding ester (1 mmol) in THF (5 mL), DIBAL-H (2.5 mmol,
1 M in THF) was added, and the mixture was stirred at 0 °C for 1–2 h. Then, the
reaction was quenched with H2O, diluted with EtOAc, and washed with 10%
solution of HCl and brine. The mixture was dried over anhydrous Na2SO4 and the
solvent removed. Products were purified by flash chromatography on silica gel
(EtOAc/hexane mixtures) and characterized by spectroscopic techniques.
General procedure for oxidation with Dess–Martin periodinane (GP-3): To a
solution of the corresponding alcohol (1 mmol) in CH2Cl2 (15 mL) at 0 °C,
Dess–Martin periodinane (1.5 mmol) was added, and the mixture was stirred at
room temperature for 1–2 h. Then, the solvent was removed, and EtOAc was
added. The organic layer was washed with a 1:1 solution of saturated NaHCO3 and
10% Na2S2O3, dried over anhydrous Na2SO4, and the solvent removed. Products
were purified by flash chromatography on silica gel (EtOAc/hexane mixtures) and
characterized by spectroscopic techniques.
General procedure for basic deprotection of esters (GP-4): To a solution of the
corresponding ester (1 mmol) in wet MeOH (30 mL), a 2 M solution of KOH in
MeOH (8–12 mmol) was added, and the mixture was stirred at room temperature
for 4–6 h. Then, a few drops of water were added, and the mixture was neutralized
by the addition of amberlyst 15 (110 mg, previously washed with CH2Cl2 and
MeOH). Products were purified by flash chromatography on silica gel (CH2Cl2/
MeOH) and characterized by spectroscopic techniques.
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The 1H and 13C NMR spectra of synthetic lipids and precursors are shown in
Supplementary Fig. 5.
Modeling granadaene and synthetic lipids. All compounds were drawn with the
ChemDraw software (PerkinElmer). Optimized structures were obtained using
Chem3D software (MM2 level) (PerkinElmer), and were visualized as .mol files
using Mercury software (The Cambridge Crystallographic Data Center). Here, the
distance between the first carbon to the last carbon of the last double bond in the
polyene chain was measured to calculate the length of the polyene chain for each
compound.
Hemolytic assays. Synthetic analogs (Table 1) were resuspended in DTS or
DMSO to achieve a concentration of 0.02 M. To test for hemolysis, 3–5 µL of
synthetic analogs were spotted onto a Red blood agar plate (TSA plate containing
5% sheep’s blood, Remel). After allowing the spots to dry for about 10 min at room
temperature, the blood agar plates incubated overnight at 37 °C in 5% CO2. Blood
agar plates were placed on a light box, and photographs were captured with the
digital SLR camera described above and processed using Photoshop CC (Adobe).
Synthetic analogs were co-incubated with human RBCs (1%) in PBS in a final
volume of 100 µL at 250, 125, and 62.5 µM for 1 h at 37 °C, after which the samples
were spun for 4 min at 3000 × g to pellet unlysed RBCs. Hemoglobin release was
measured by recording the absorbance at 420 nm of the supernatants obtained
from above. Percent hemolysis relative to Triton X-100 (0.1%)-treated positive
controls and PBS-treated negative controls was calculated.
Isolation of T and B cells from human adult blood. Approximately 15 mL of
blood was collected from healthy human adults into EDTA tubes (BD Biosciences).
Immediately following collection, CD4+ or B cells were isolated from the blood
using the appropriate RosetteSep Enrichment Cocktail (StemCell) along with
SepMate tubes (StemCell), as per the manufacturer’s instructions. Cells were then
pelleted, and any residual RBCs were removed by re-suspending the cell pellet in
RBC lysis solution (150 mM NH4Cl, 1 mM NaHCO3) for 15 min at room tem-
perature. Following RBC lysis, cells were washed with Roswell Park Memorial
Institute 1640 tissue culture medium containing L-glutamine (Corning; hereafter
referred to as RPMI-G). Cell purity was assessed by examining the proportion of
cells positive for the appropriate markers using flow cytometry. Briefly, ~1 × 106
cells from the purification preparation or 1 × 106 cells from whole blood (following
two RBC lysis steps, as described above) were incubated with Fc receptor block
(1:200; BD Biosciences) for 15 min at room temperature. Then, immunofluorescent
antibodies were added to the cells and cells were incubated for 30 min at room
temperature. B cell preparations were stained with CD19-PerCP/Cy5.5 (3:100;
BioLegend); CD4+ T cell preparations were stained with CD3-FITC (1:10; BD
Biosciences), CD4-V450 (1:10; BD Biosciences), and CD8-PerCP/Cy5.5 (1:10;
BioLegend). Stained cells were washed twice in FACS (fluorescence-activated cell
sorting) buffer (1 mM EDTA, 25 mM HEPES, 1% bovine serum albumin (w/v) in
PBS) and were analyzed immediately on an LSR II flow cytometer (BD Bios-
ciences). Single-stained fluorochrome-reactive AbC beads (Thermo Fisher) and
unstained cells were used for compensation. Data were analyzed using FlowJo v.
10.1 (FlowJo, LLC).
Analysis for cytotoxicity. T and B cells were isolated as described above. T or B
cells were seeded with 2.5 × 106 cells in each well in 90 µL RPMI-G. Hyper-
hemolytic GBS (WT NCTC10/84) and non-hemolytic GBS (NCTC10/84ΔcylE)
were grown to mid-exponential growth phase (OD600= 0.3), washed twice in
sterile PBS, and added to cells at a multiplicity of infection (MOI) of 10. MOIs were
confirmed by dilution plating. Additionally, granadaene in DTS from WT GBS was
added to cells at a final concentration of 0.5 µM, and R-P4 was added to cells at a
final concentration of 20 μM. As positive and negative controls for all assays, cells
were incubated in 0.1% Triton X-100 (Sigma-Aldrich) or sterile PBS, respectively.
After 1 h incubation at 37 °C, cells were analyzed for cytotoxicity by the presence of
cytoplasmic lactate dehydrogenase (LDH) in cell supernatants using the Colori-
metric LDH kit (Clontech), as per the manufacturer’s instructions. Percent cyto-
toxicity was calculated by normalizing to PBS-treated cells (0% cell death) and
Triton X-100-treated cells (100% cell death), as described6,7,24.
Uptake of PI and AV. PI uptake and AV staining were measured concurrently as
described24. To this end, isolated T and B cells from above were washed in PBS and
resuspended in AV binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2
in PBS) at a concentration of ~3.33 × 106 cells/mL. Cells were then incubated with
AV-Alexa Fluor 488 (1:20; Invitrogen) and PI (12.5 µg/mL; Life Technologies) for
15 min at room temperature, protected from light. Cells were then diluted by a
factor of 5 in AV binding buffer into FACS tubes (BD Biosciences) and treated with
hyper-hemolytic GBS or non-hemolytic GBS at an MOI of 10 or granadaene
(0.5 µM) or an equivalent volume of GBSΔcylE extract. PI uptake and AV staining
were measured using an LSR II flow cytometer (BD Biosciences) immediately
following inoculation (0 min time point) and various times after inoculation
(15, 30 min). Gates for PI+ and AV+ cells were determined using unstained and
single-stained controls.
Scanning electron microscopy. Samples were processed for SEM by the Electron
Microscopy Core at Fred Hutch Cancer Research Center as before6,24,26. To this
end, cells were washed in PBS and resuspended in one volume of 1/2 Karnovsky’s
fixative (2% paraformaldehyde, 2.5% glutaraldehyde, 2.5 mM CaCl2 in 0.1 M
cacodylate buffer, pH 7.2) and then were laid down on a poly-L-lysine coverslip for
30 min The coverslip with cells were washed in 0.1 M cacodylate buffer three times
for 10 min each. The cells were post fixed with OsO4 for 2 h at 4 °C and then
washed in 0.1 M cacodylate buffer three times for 10 min each. Samples were
dehydrated using EtOH at 50%, 70%, and 95% for 25 min each, followed by two
changes of 100% EtOH for 20 min. The cells were then treated with 1/2 volume
100% EtOH and 1/2 volume HMDS (hexamethyldisilazane) for 20 min twice and
100% HMDS twice for 20 min each. Using fresh HMDS, the coverslips were slightly
covered and allowed to dry overnight or until the HMDS had evaporated. Speci-
mens were mounted onto a stub containing carbon conductive tabs and sputter
coated with a gold-palladium target, and images were obtained using a JEOL JSM
6610LV with JEOL Acquisition System software.
Stimulation of CD4+ T and B cells. Primary human CD4+ T and B cells were
isolated from the blood of healthy human adults, as described above. Cells were
seeded at ~1 × 106 cells/mL in RPMI-G on a TC-treated 96-well plate (180 μL in
each well). CD4+ T cells were stimulated with immobilized anti-human CD3ε
(0.5 μg; BD Biosciences) and PMA (10 ng/mL; Sigma), as described46,47. B cells
were stimulated with human IL-4 (20 ng/mL; Sigma) and anti-human CD40
monoclonal antibody (5 μg/mL; Enzo, clone mAb 89), as described48. Immediately
following stimulation, cells were treated with either PBS or R-P4 (20 μM) in
technical triplicate. As controls, a group of CD4+ T and B cells received no sti-
mulus and no treatment (designated as “PBS (unstimulated)”). After incubating for
48 h at 37 °C, cells were treated with human Fc block (1:200; BD Biosciences),
stained with anti-CD69-PE/Cy7 (10 μL/test; BD Biosciences, clone FN50), washed,
and resuspended in DAPI (0.5 μM; Thermo). Cells were run on an LSR II flow
cytometer (BD Biosciences). Unstained cells, single-stained DAPI+ cells, and
single-stained PE/Cy7+ beads were used as compensation controls. Data were
analyzed using the FlowJo software, and gates for DAPI− and CD69+ events were
determined using fluorescence minus one or unstained controls. For the gating
strategy used to calculate percent CD69+ cells of single cells, see Supplementary
Fig. 5.
Vaccination. The first vaccine emulsion was prepared by mixing Complete
Freund’s Adjuvant (Invivogen) and R-P4 (20 μM dissolved in sterile PBS) at a ratio
of 1:1. For the first vaccination, 100 μL of the emulsion was injected (IP) into male
(n= 12) and female (n= 12) C57BL6/J mice (obtained from Jackson Laboratories).
Fourteen days after initial vaccination, mice were injected with 100 μL of freshly
prepared vaccine emulsion in Incomplete Freund’s Adjuvant (Invivogen).
Adjuvant-only emulsions were made by mixing the appropriate adjuvant in sterile
PBS at a ratio of 1:1. Adjuvant-only control mice were injected (IP) in male (n=
12) and female (n= 12) mice on the same schedule as analog-vaccinated mice.
Immunoblots. Blood was collected from 10 vaccinated mice and 10 adjuvant-only
control C57BL6/J mice via cardiac puncture 21 days after initial vaccination. Blood
was centrifuged at 3000 x g for 15 min at 4 °C, and unpelleted plasma was collected
and stored at −80 °C.
Granadaene (dissolved in DMSO+ 0.1% trifluoroacetic acid) was diluted to
25 μM in PBS and was pipetted (4 μL) onto pre-cut squares of Immoblion-FL
PVDF membrane (Sigma-Aldrich). After drying for ~1 h, membranes were treated
with Odyssey blocking buffer in PBS (LI-COR) for 1 h while shaking at room
temperature. Blocking buffer was removed, and each membrane was probed with
an aliquot of plasma from an analog-vaccinated or adjuvant-only mouse diluted
1:250 in buffer solution (1:1 Odyssey blocking buffer and PBS with 0.02% Tween-
20). After shaking overnight at 4 °C, membranes were washed three times in wash
solution (TBS+ 0.02% Tween-20), and then probed with Alexa Fluor 680 goat
anti-mouse IgG (Invitrogen) (1:2500 in buffer solution). Membranes incubated
with secondary antibody for 45 min at room temperature were protected from
light. Then, membranes were washed three times in wash solution and twice in PBS
and imaged using the LI-COR Odyssey Infrared Imaging System. Signal intensity
of each spot was determined using the Image J software.
Granadaene ex vivo inhibition assay. Diluted plasma (1:1000) from analog-
vaccinated mice or adjuvant-control mice (n= 10/group) were pre-incubated with
purified granadaene (0.3 μM in DTS) for 1 h at room temperature. The samples
were then incubated with 100 µL of EDTA-treated human red blood cells (1% in
PBS) for 1 h at 37 °C. As described above, hemoglobin release in cell supernatants
was measured using the SpectraMax i3x plate reader (absorbance at 420 nm), and
percent hemolysis relative to Triton X-100 (0.1%)/granadaene-treated positive
controls (100% hemolysis) and PBS-treated negative controls (0% hemolysis) was
calculated.
Murine model of GBS infection. Twenty-one days after initial vaccination, analog-
vaccinated (n= 24) and adjuvant-only mice (n= 24) were injected (IP) with~1 ×
108 CFU of GBS strain NCTC10/84 suspended in sterile PBS (100 μL injected). At
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24 h, all mice were euthanized. Blood was collected via cardiac puncture into
heparin tubes (BD). Organs (brain, lung, and spleen) were collected in 1 mL sterile
PBS and homogenized. GBS CFU in the blood and each organ was determined by
dilution plating on tryptic soy agar (Difco Laboratories). All uninfected mice were
housed in specific pathogen-free barrier facilities in the SCRI vivarium, and all
GBS-infected mice were housed in ABSL-2 facilities in the SCRI vivarium, as per
the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health (8th Edition).
Statistical analysis. A value of p < 0.05 was considered significant. Non-significant
p values are denoted as “n.s.” in the figures. For in vitro assays, an unpaired, two-
tailed Student’s t test or one-way analysis of variance (ANOVA) with Tukey’s post
test was employed as appropriate to analyze differences between treatment groups,
unless otherwise noted. All in vitro experiments were performed three times
(unless otherwise noted) in technical triplicate. The correlation between IgG signal
intensity and granadaene inhibition was analyzed using a Pearson’s correlation test.
Differences in CFU in blood and peripheral organs of vaccinated and unvaccinated
mice were determined using Mann–Whitney test, as Gaussian distribution was not
assumed in these datasets. GraphPad Prism (version 7.03) was used to compute all
statistical tests.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Fig. 1b, c, d, e, Fig. 3a, d, Fig. 4a, b, c, and Fig. 5b, c, d, and
Supplementary Fig. 3b, c and Supplementary Fig. 4 are provided as a Source Data file. All
other relevant data supporting the key findings of this study are available within the
article and its Supplementary Information file or from the corresponding authors upon
request.
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